{"id":160692,"date":"2014-11-21T07:46:38","date_gmt":"2014-11-21T12:46:38","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/panel-based-genetic-diagnostic-testing-for-inherited-eye-diseases-is-highly-accurate-and-more-sensitive-than-exome.php"},"modified":"2014-11-21T07:46:38","modified_gmt":"2014-11-21T12:46:38","slug":"panel-based-genetic-diagnostic-testing-for-inherited-eye-diseases-is-highly-accurate-and-more-sensitive-than-exome","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/panel-based-genetic-diagnostic-testing-for-inherited-eye-diseases-is-highly-accurate-and-more-sensitive-than-exome.php","title":{"rendered":"Panel-Based Genetic Diagnostic Testing for Inherited Eye Diseases Is Highly Accurate and More Sensitive Than Exome &#8230;"},"content":{"rendered":"<p><p>Contact Information         <\/p>\n<p>      Available for logged-in reporters only    <\/p>\n<p>    Newswise  BOSTON (Nov. 20, 2014) Investigators at    Massachusetts Eye and Ear and Harvard Medical School Department    of Ophthalmology and colleagues reported the development and    characterization of a comprehensive genetic test for inherited    eye disorders in the online version of the Nature journal    Genetics In Medicine today. The Genetic Eye Disease    (GEDi) test includes all of the genes known to harbor mutations    that cause inherited retinal degenerations, optic atrophy and    early onset glaucoma. These disorders are important causes of    vision loss, and genetic treatments such as gene therapy hold    promise for preserving vision in affected individuals. The GEDi    test is offered on a CLIA-certified basis through the Ocular    Genomics Institute (OGI) at Mass. Eye and Ear.  <\/p>\n<p>    The retina is the neural tissue in the back of the eye that    initiates vision. It is responsible for receiving light signals    and converting them into neurologic signals, which are then    transmitted via the optic nerve to the brain so that we can    see. Mutations that disrupt vision by damaging the retina and    optic nerve have been identified in more than 200 genes. This    genetic diversity made genetic diagnostic testing difficult    until the recent development of high throughput genomic    techniques. The GEDi test uses targeted capture and next    generation sequencing techniques to sequence 226 genes known to    cause inherited eye disorders. Future versions of the test will    also include genes responsible for eye movement disorders    (strabismus) and other inherited eye conditions.  <\/p>\n<p>    Gene panel-based tests for inherited eye disorders have been    previously reported, but none of these have been as thoroughly    characterized with regard to their performance in a diagnostic    setting as the GEDi test. Stringent tests of accuracy and    reproducibility showed that the GEDi test is both highly    accurate and reproducible. This type of validation testing is    recommended by the American College of Medical Genetics and    Genomics, but few other genetic tests have been characterized    in as much detail as the GEDi test. The results reported show    that the GEDi test is 98 percent accurate at detecting spelling    variations or mutations in the genetic code of inherited eye    disease genes, and is highly reproducible between test runs. In    contrast, the technique whole exome sequencing  in which the    coding regions of all genes are sequenced, and which is being    employed commonly in clinical settingswas 88 percent accurate    at detecting genetic variants in the same genes.  <\/p>\n<p>    The results we obtained for the GEDi test have broad    implications and show that panel-based testing focused on the    specific genes associated with genetic conditions offers    important advantages over whole exome sequencing, said Janey    Wiggs, M.D., Ph.D., director of the Genetic Diagnostic Testing    Service of the OGI, and the Paul Austin Chandler Associate    Professor of Ophthalmology, Harvard Medical School.  <\/p>\n<p>    Investigators in the OGI and other centers around the United    States and the world are optimistic that treatments targeting    the underlying genetic cause of inherited eye disorders can be    applied broadly to preserve vision. One especially promising    approach is gene therapy, in which a correct copy of the    misspelled or mutant gene responsible for disease is added to    the affected cells in the retina. Reports of early results from    clinical trials of gene therapies for two inherited retinal    degenerative disorders have shown that this treatment can be    performed safely, and that subjects treated in these trials    experienced significant improvements in or preservation of    vision. Clinical trials of gene therapies for three additional    genetic forms of inherited retinal degeneration are currently    in progress, and more are on the way. Given the potential of    gene and genetic therapies, improved genetic diagnostic testing    for patients with genetic eye disorders such as that offered    with the GEDi test is especially important.  <\/p>\n<p>    About Massachusetts Eye and Ear    Mass. Eye and Ear clinicians and scientists are driven by a    mission to find cures for blindness, deafness and diseases of    the head and neck. After uniting with Schepens Eye Research    Institute in 2011, Mass. Eye and Ear in Boston became the    world's largest vision and hearing research center, offering    hope and healing to patients everywhere through discovery and    innovation. Mass. Eye and Ear is a Harvard Medical School    teaching hospital and trains future medical leaders in    ophthalmology and otolaryngology, through residency as well as    clinical and research fellowships. Internationally acclaimed    since its founding in 1824, Mass. Eye and Ear employs    full-time, board-certified physicians who offer high-quality    and affordable specialty care that ranges from the routine to    the very complex. U.S. News & World Reports Best    Hospitals Survey has consistently ranked the Mass. Eye and Ear    Departments of Otolaryngology and Ophthalmology as among the    top hospitals in the nation. Mass. Eye and Ear is home to the    Ocular Genomics Institute which aims to translate the promise    of precision medicine into clinical care for ophthalmic    disorders. For more information about life-changing care and    research, or to learn how you can help, please visit    MassEyeAndEar.org.  <\/p>\n<p>    Reference:    Consugar MB*, Navarro-Gomez D*, Place EM*, Bujakowska KM, Sousa    ME, Fonseca-Kelly ZD, Taub DG, Janessian M, Wang DY, Au ED,    Sims KB, Sweetser DA, Fulton AB, Liu Q, Wiggs JL,Gai X, Pierce    EA. Panel-based Genetic Diagnostic Testing for Inherited Eye    Diseases is Highly Accurate and Reproducible and More Sensitive    for Variant Detection Than Exome Sequencing. Genetics In    Medicine, In Press. (*Co-first authors).  <\/p>\n<p>    Grant support:    This work was supported by grants from the National Institutes    of Health (EY012910, and P30EY014104), the March of Dimes and    the Foundation Fighting Blindness.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View original post here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/626456\/?sc=rsmn\/RK=0\/RS=byO0IBrOMmpi4YCa.Xc.4S0BOA8-\" title=\"Panel-Based Genetic Diagnostic Testing for Inherited Eye Diseases Is Highly Accurate and More Sensitive Than Exome ...\">Panel-Based Genetic Diagnostic Testing for Inherited Eye Diseases Is Highly Accurate and More Sensitive Than Exome ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Contact Information Available for logged-in reporters only Newswise BOSTON (Nov. 20, 2014) Investigators at Massachusetts Eye and Ear and Harvard Medical School Department of Ophthalmology and colleagues reported the development and characterization of a comprehensive genetic test for inherited eye disorders in the online version of the Nature journal Genetics In Medicine today.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/panel-based-genetic-diagnostic-testing-for-inherited-eye-diseases-is-highly-accurate-and-more-sensitive-than-exome.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-160692","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/160692"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=160692"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/160692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=160692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=160692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=160692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}